切换到布里莫尼丁/里帕苏迪尔 固定组合从布里莫尼丁 + 里帕苏迪尔
Kenji Inoue1, Minako Shiokawa1, Shiho Kunimatsu-Sanuki2
1Inouye Eye Hospital, Tokyo, Japan.
Clinical ophthalmology (Auckland, N.Z.)
|February 12, 2024
概括
切换到布里莫尼丁 + 里帕苏迪尔固定组合 (BRFC) 眼滴维持了眼内压力 (IOP) 六个月. 这种新的固定组合在以前接受单独治疗的青光眼患者中显示出良好的安全性和可用性.
科学领域:
- 眼科医生 眼科 眼科
- 玻璃眼研究研究 玻璃眼研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 固定的组合眼滴比单独的治疗方法具有优势.
- 切换到布里莫尼丁 + 里帕苏迪尔固定组合 (BRFC) 眼滴的疗效和安全性需要研究.
研究的目的:
- 从单独的布里莫尼丁和利帕苏迪尔治疗转换后,评估BRFC眼滴的6个月的安全性,可用性和眼内压力 (IOP) 降低功效.
- 评估患者报告的结果和对固定组合治疗的偏好.
主要方法:
- 追溯性研究69名患有初级开角青光眼的患者从布里莫尼丁 + 里帕苏迪尔转换为BRFC而没有洗.
- 转换前和转换后3个月和6个月的IOP的比较.
- 通过调查问卷调查不良反应,停止治疗和可用性.
主要成果:
- 切换后,内压保持稳定 (15.1 mmHg基线,6个月内14.6 mmHg).
- 5.8%的患者出现了不良反应;7.2%的患者停止治疗.
- 大多数患者报告说,眼睛疼痛,和视力模糊等症状没有变化或改善,强烈偏好固定组合 (76.8%).
结论:
- 切换到布里莫尼丁 + 里帕苏迪尔固定组合 (BRFC) 眼滴有效保持至少六个月的内腔压力.
- BRFC 证明了令人满意的安全性和舒适性,这使得它成为以前接受单独布里莫尼丁和利帕苏迪尔治疗的患者的可行选择.
相关概念视频
01:27Open Angle Glaucoma: Treatment
449
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
449
01:01Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
01:28Angle Closure Glaucoma: Treatment
499
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
499
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431